File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection

TitleCirculating microRNAs as Specific Biomarkers for Breast Cancer Detection
Authors
Issue Date2013
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
Citation
Plos One, 2013, v. 8 n. 1 How to Cite?
AbstractBackground: We previously showed microRNAs (miRNAs) in plasma are potential biomarkers for colorectal cancer detection. Here, we aimed to develop specific blood-based miRNA assay for breast cancer detection. Methodology/Principal Findings: TaqMan-based miRNA profiling was performed in tumor, adjacent non-tumor, corresponding plasma from breast cancer patients, and plasma from matched healthy controls. All putative markers identified were verified in a training set of breast cancer patients. Selected markers were validated in a case-control cohort of 170 breast cancer patients, 100 controls, and 95 other types of cancers and then blindly validated in an independent set of 70 breast cancer patients and 50 healthy controls. Profiling results showed 8 miRNAs were concordantly up-regulated and 1 miRNA was concordantly down-regulated in both plasma and tumor tissue of breast cancer patients. Of the 8 up-regulated miRNAs, only 3 were significantly elevated (p<0.0001) before surgery and reduced after surgery in the training set. Results from the validation cohort showed that a combination of miR-145 and miR-451 was the best biomarker (p<0.0001) in discriminating breast cancer from healthy controls and all other types of cancers. In the blind validation, these plasma markers yielded Receiver Operating Characteristic (ROC) curve area of 0.931. The positive predictive value was 88% and the negative predictive value was 92%. Altered levels of these miRNAs in plasma have been detected not only in advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was 96%. Conclusions: These results suggested that these circulating miRNAs could be a potential specific biomarker for breast cancer screening. © 2013 Ng et al.
Persistent Identifierhttp://hdl.handle.net/10722/181979
ISSN
2023 Impact Factor: 2.9
2023 SCImago Journal Rankings: 0.839
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, EKOen_HK
dc.contributor.authorLi, Ren_HK
dc.contributor.authorShin, VYen_HK
dc.contributor.authorJin, HCen_HK
dc.contributor.authorLeung, CPHen_HK
dc.contributor.authorMa, ESKen_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorChua, Den_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorLaw, WLen_HK
dc.contributor.authorLaw, SYKen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorKwong, Aen_HK
dc.date.accessioned2013-04-17T07:16:00Z-
dc.date.available2013-04-17T07:16:00Z-
dc.date.issued2013en_HK
dc.identifier.citationPlos One, 2013, v. 8 n. 1en_HK
dc.identifier.issn1932-6203en_HK
dc.identifier.urihttp://hdl.handle.net/10722/181979-
dc.description.abstractBackground: We previously showed microRNAs (miRNAs) in plasma are potential biomarkers for colorectal cancer detection. Here, we aimed to develop specific blood-based miRNA assay for breast cancer detection. Methodology/Principal Findings: TaqMan-based miRNA profiling was performed in tumor, adjacent non-tumor, corresponding plasma from breast cancer patients, and plasma from matched healthy controls. All putative markers identified were verified in a training set of breast cancer patients. Selected markers were validated in a case-control cohort of 170 breast cancer patients, 100 controls, and 95 other types of cancers and then blindly validated in an independent set of 70 breast cancer patients and 50 healthy controls. Profiling results showed 8 miRNAs were concordantly up-regulated and 1 miRNA was concordantly down-regulated in both plasma and tumor tissue of breast cancer patients. Of the 8 up-regulated miRNAs, only 3 were significantly elevated (p<0.0001) before surgery and reduced after surgery in the training set. Results from the validation cohort showed that a combination of miR-145 and miR-451 was the best biomarker (p<0.0001) in discriminating breast cancer from healthy controls and all other types of cancers. In the blind validation, these plasma markers yielded Receiver Operating Characteristic (ROC) curve area of 0.931. The positive predictive value was 88% and the negative predictive value was 92%. Altered levels of these miRNAs in plasma have been detected not only in advanced stages but also early stages of tumors. The positive predictive value for ductal carcinoma in situ (DCIS) cases was 96%. Conclusions: These results suggested that these circulating miRNAs could be a potential specific biomarker for breast cancer screening. © 2013 Ng et al.en_HK
dc.languageengen_US
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.actionen_HK
dc.relation.ispartofPLoS ONEen_HK
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleCirculating microRNAs as Specific Biomarkers for Breast Cancer Detectionen_HK
dc.typeArticleen_HK
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_HK
dc.identifier.authorityKwong, A=rp01734en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1371/journal.pone.0053141en_HK
dc.identifier.pmid23301032-
dc.identifier.pmcidPMC3536802-
dc.identifier.scopuseid_2-s2.0-84871872764en_HK
dc.identifier.hkuros213835en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84871872764&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue1en_HK
dc.identifier.spagee53141en_US
dc.identifier.epagee53141en_US
dc.identifier.isiWOS:000313480000032-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNg, EKO=55356547500en_HK
dc.identifier.scopusauthoridLi, R=55544541500en_HK
dc.identifier.scopusauthoridShin, VY=55543654800en_HK
dc.identifier.scopusauthoridJin, HC=24577511700en_HK
dc.identifier.scopusauthoridLeung, CPH=41761959600en_HK
dc.identifier.scopusauthoridMa, ESK=55356328300en_HK
dc.identifier.scopusauthoridPang, R=55544987200en_HK
dc.identifier.scopusauthoridChua, D=55543582800en_HK
dc.identifier.scopusauthoridChu, KM=55544062600en_HK
dc.identifier.scopusauthoridLaw, WL=55545458600en_HK
dc.identifier.scopusauthoridLaw, SYK=55544927000en_HK
dc.identifier.scopusauthoridPoon, RTP=55274361000en_HK
dc.identifier.scopusauthoridKwong, A=8913654300en_HK
dc.identifier.issnl1932-6203-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats